NASDAQ:IART - Integra Lifesciences Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$63.22 +0.28 (+0.44 %)
(As of 07/20/2018 08:35 AM ET)
Previous Close$62.94
Today's Range$62.55 - $63.64
52-Week Range$41.51 - $67.50
Volume339,918 shs
Average Volume899,763 shs
Market Capitalization$5.53 billion
P/E Ratio32.59
Dividend YieldN/A
Beta0.63
Integra Lifesciences logoIntegra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. It offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. The company also sells approximately 60,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, it provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, the company sells hardware products, such as bone and joint fixation, and joint replacement devices; implants; and instruments, which provide for the orthopedic reconstruction of bone in the hand, wrist, elbow, and shoulder, as well as the foot, ankle, and leg below the knee in the extremity bone and joint reconstruction procedures. Integra LifeSciences Holdings Corporation offers its products directly through various sales forces and other distribution channels in the United States, Europe, and internationally. The company was founded in 1989 and is headquartered in Plainsboro, New Jersey.

Receive IART News and Ratings via Email

Sign-up to receive the latest news and ratings for IART and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Analytical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:IART
CUSIP45798520
Phone609-275-0500

Debt

Debt-to-Equity Ratio1.77
Current Ratio2.53
Quick Ratio1.66

Price-To-Earnings

Trailing P/E Ratio32.59
Forward P/E Ratio26.23
P/E Growth1.89

Sales & Book Value

Annual Sales$1.19 billion
Price / Sales4.68
Cash Flow$3.1359 per share
Price / Cash20.16
Book Value$12.26 per share
Price / Book5.16

Profitability

EPS (Most Recent Fiscal Year)$1.94
Net Income$64.74 million
Net Margins5.39%
Return on Equity17.90%
Return on Assets6.14%

Miscellaneous

Employees4,400
Outstanding Shares87,880,000
Market Cap$5,531.04

Integra Lifesciences (NASDAQ:IART) Frequently Asked Questions

What is Integra Lifesciences' stock symbol?

Integra Lifesciences trades on the NASDAQ under the ticker symbol "IART."

When did Integra Lifesciences' stock split? How did Integra Lifesciences' stock split work?

Integra Lifesciences's stock split on Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly minted shares were distributed to shareholders after the market closes on Wednesday, December 21st 2016. An investor that had 100 shares of Integra Lifesciences stock prior to the split would have 200 shares after the split.

How were Integra Lifesciences' earnings last quarter?

Integra Lifesciences Holdings Corp (NASDAQ:IART) released its quarterly earnings data on Wednesday, April, 25th. The life sciences company reported $0.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.49 by $0.09. The life sciences company had revenue of $357.10 million for the quarter, compared to analysts' expectations of $349.15 million. Integra Lifesciences had a return on equity of 17.90% and a net margin of 5.39%. The company's revenue for the quarter was up 38.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.39 EPS. View Integra Lifesciences' Earnings History.

When is Integra Lifesciences' next earnings date?

Integra Lifesciences is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for Integra Lifesciences.

What guidance has Integra Lifesciences issued on next quarter's earnings?

Integra Lifesciences updated its FY18 earnings guidance on Wednesday, April, 25th. The company provided EPS guidance of $2.34-2.42 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.33. The company issued revenue guidance of $1.47-1.49 billion, compared to the consensus revenue estimate of $1.48 billion.

What price target have analysts set for IART?

14 Wall Street analysts have issued 1 year price objectives for Integra Lifesciences' stock. Their predictions range from $50.00 to $74.00. On average, they anticipate Integra Lifesciences' share price to reach $59.6667 in the next twelve months. This suggests that the stock has a possible downside of 5.6%. View Analyst Ratings for Integra Lifesciences.

What is the consensus analysts' recommendation for Integra Lifesciences?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Integra Lifesciences in the last year. There are currently 11 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

What are Wall Street analysts saying about Integra Lifesciences stock?

Here are some recent quotes from research analysts about Integra Lifesciences stock:
  • 1. According to Zacks Investment Research, "Significant gross margin contractions caused by escalating costs have been a major headwind for Integra Lifesciences. Added to this, a tough competitive landscape adds to the company’s woes. Despite these hurdles, Integra Lifesciences has outperformed its industry over the last three months. Solid growth across all business segments has been the key growth catalyst. Integra’s successful progress with its channel expansion strategy and Codman integration buoy optimism. Notably, the company announced plans within Orthopedics and Tissue Technologies segment to expand its sales channel, improve focus and competitiveness and better align the company’s product portfolio with clinical customers. Moreover, the strong investments in research and development is encouraging. The company’s promising guidance also instills confidence in the stock." (7/10/2018)
  • 2. Cantor Fitzgerald analysts commented, "We maintain our Neutral rating and 12-month price target of $59 on IART. Although we view IART’s long-range plan as impressive, we believe execution over the next few quarters is critical to restoring investor confidence in the stock. We think it is appropriate to stay on the sidelines at this time, but we might become more positive on the stock if the company were to execute on its integration and salesforce restructuring goals. We think IART is fairly valued at current levels, appropriately balancing the long-term opportunities with the risk of near-term disruption from the Codman acquisition and the changes to the OTT sales channel structure." (6/12/2018)

Who are some of Integra Lifesciences' key competitors?

Who are Integra Lifesciences' key executives?

Integra Lifesciences' management team includes the folowing people:
  • Mr. Peter J. Arduini, Pres, CEO & Director (Age 53)
  • Dr. Richard E. Caruso Ph.D., Founder and Chairman Emeritus (Age 75)
  • Mr. Glenn G. Coleman, Corp. VP & CFO (Age 50)
  • Mr. Richard D. Gorelick, Corp. VP of Admin., Gen. Counsel & Sec. (Age 57)
  • Mr. Daniel L. Reuvers, Corp. VP and Pres of Specialty Surgical Solutions (Age 55)

Has Integra Lifesciences been receiving favorable news coverage?

Headlines about IART stock have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Integra Lifesciences earned a coverage optimism score of 0.24 on Accern's scale. They also gave news coverage about the life sciences company an impact score of 47.11 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Who are Integra Lifesciences' major shareholders?

Integra Lifesciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (1.08%), Retirement Systems of Alabama (0.10%), Mitsubishi UFJ Asset Management UK Ltd. (0.02%), Louisiana State Employees Retirement System (0.02%), Amalgamated Bank (0.02%) and Municipal Employees Retirement System of Michigan (0.02%). Company insiders that own Integra Lifesciences stock include Barbara B Hill, Christian S Schade, Daniel L Reuvers, Donald E Morel Jr, Glenn Coleman, James M Sullivan, Jeffrey Mosebrook, Joseph Vinhais, Keith Bradley, Peter J Arduini, Raymond G Murphy, Richard D Gorelick, Richard E Caruso and Stuart Essig. View Institutional Ownership Trends for Integra Lifesciences.

Which major investors are selling Integra Lifesciences stock?

IART stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Fisher Asset Management LLC, Louisiana State Employees Retirement System and Municipal Employees Retirement System of Michigan. Company insiders that have sold Integra Lifesciences company stock in the last year include Christian S Schade, Daniel L Reuvers, Glenn Coleman, Jeffrey Mosebrook, Joseph Vinhais, Keith Bradley, Richard D Gorelick, Richard E Caruso and Stuart Essig. View Insider Buying and Selling for Integra Lifesciences.

Which major investors are buying Integra Lifesciences stock?

IART stock was acquired by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, Mitsubishi UFJ Asset Management UK Ltd., Amalgamated Bank, Bank of Montreal Can and World Asset Management Inc. Company insiders that have bought Integra Lifesciences stock in the last two years include Barbara B Hill and Donald E Morel Jr. View Insider Buying and Selling for Integra Lifesciences.

How do I buy shares of Integra Lifesciences?

Shares of IART can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Integra Lifesciences' stock price today?

One share of IART stock can currently be purchased for approximately $63.22.

How big of a company is Integra Lifesciences?

Integra Lifesciences has a market capitalization of $5.53 billion and generates $1.19 billion in revenue each year. The life sciences company earns $64.74 million in net income (profit) each year or $1.94 on an earnings per share basis. Integra Lifesciences employs 4,400 workers across the globe.

How can I contact Integra Lifesciences?

Integra Lifesciences' mailing address is 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536. The life sciences company can be reached via phone at 609-275-0500 or via email at [email protected]


MarketBeat Community Rating for Integra Lifesciences (NASDAQ IART)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  323 (Vote Outperform)
Underperform Votes:  344 (Vote Underperform)
Total Votes:  667
MarketBeat's community ratings are surveys of what our community members think about Integra Lifesciences and other stocks. Vote "Outperform" if you believe IART will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IART will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.